Literature DB >> 15892760

Cannula-associated Staphylococcus aureus bacteraemia: outcome in relation to treatment.

M G Thomas1, A J Morris.   

Abstract

BACKGROUND: Despite the frequency of cannula-associated Staphylococcus aureus bacteraemia (CASAB) there is uncertainty regarding the duration of treatment required. AIM: To determine the relationship between the duration and type of treatment for CASAB and subsequent relapse with deep-seated S. aureus infection.
METHODS: We prospectively studied 276 patients with CASAB. Patients were followed for at least 8 weeks after completion of antibiotic treatment. Initial and subsequent isolates of S. aureus were compared using molecular methods to determine strain similarity.
RESULTS: Initial mortality was 9% (26 of 276) and a complicating focus of infection presented during initial treatment in 6% (15 of 250) of the survivors. There were nine relapses of deep-seated infection from the strain causing the original infection. Relapses were equally common following peripheral CASAB and central CASAB. There was no relationship between the duration of treatment and the rate of relapse of deep-seated infection (P = 0.24). This observation held true regardless of whether the duration of treatment was analysed as < or = 7 versus > or = 8, < or =10 versus > or =11, or < or=14 versus > or =15 days (P = 0.62, 0.87 and 0.16, respectively).
CONCLUSION: Episodes of peripheral CASAB pose an equal risk of relapse to central cannula-related episodes. Although further studies are needed to determine the optimal treatment of CASAB, our study strongly suggests that more than 14 days treatment is excessive for most patients who respond promptly to cannula removal and antibiotic treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15892760     DOI: 10.1111/j.1445-5994.2005.00823.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  6 in total

1.  Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study.

Authors:  Yong Pil Chong; Song Mi Moon; Kyung-Mi Bang; Hyun Jung Park; So-Youn Park; Mi-Na Kim; Ki-Ho Park; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jin-Yong Jeong; Jun Hee Woo; Yang Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

2.  Efficacy of Early Oral Switch with β-Lactams for Low-Risk Staphylococcus aureus Bacteremia.

Authors:  Olivia Bupha-Intr; Tim Blackmore; Max Bloomfield
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 3.  Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.

Authors:  Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 4.  The Impact of Hypoxia on the Host-Pathogen Interaction between Neutrophils and Staphylococcus aureus.

Authors:  Natalia H Hajdamowicz; Rebecca C Hull; Simon J Foster; Alison M Condliffe
Journal:  Int J Mol Sci       Date:  2019-11-07       Impact factor: 6.208

Review 5.  Infection in the critically ill--questions we should be asking.

Authors:  John R Prowle; Sarah Heenen; Mervyn Singer
Journal:  J Antimicrob Chemother       Date:  2011-04       Impact factor: 5.790

6.  Duration of antibiotic therapy for Staphylococcus aureus bacteraemia: the long and the short of it.

Authors:  E M Eichenberger; V G Fowler; T L Holland
Journal:  Clin Microbiol Infect       Date:  2020-01-20       Impact factor: 13.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.